Purchase MEO-PV9
Discount program, second order - 5%OFF, third order - 7% OFF
With us securely! - re-shipment guarantees.
We always offer new legal products of impeccable quality.
Please make sure that the product is legal in your country and not under control before ordering.
We do not sell pharmaceutical products or controlled products.
Where to buy MEO-PV9 for sale
4-meo-pv9 is a psychoactive drug that acts as an agonist for multiple serotonin receptors, including the 5-HT2A receptor. The 4-meo-pv9 chemical formula is C19H29NO2. 4-meo-pv9 molar mass is 303.44 g/mol, the density is 0.930 g/cm3, and the melting point is <104 °C
4-meo-pv9 is a structural analog of alpha-PV9, a more potent analog of 4-methylpv9 than the parent pyrrolidinone. It is a more potent cannabinoid agonist than the related compound 4-MeO-PV13 and the cyclohexanone derivative PV18
It has been shown that the close structural analog of PV9 is a more potent cannabinoid agonist than the parent pyrrolidinone, PV13, along with its cyclohexanone derivative, PV18.
This compound is an analog of alpha-pyrrolidinopentiophenone, a cannabinoid agonist. It is more potent than its parent, pyrrolidinone and related cyclohexanone derivatives.
MEO-PV9 is a significant cannabinoid agonist discovered in a synthetic chemistry effort to expand the chemical space of selective CB1 receptor agonists. It displays higher potency than PV13 and β-cyclohexyl-morpholino derivative PV18, with IC50 values of 2.5 nM and 5.5 nM, respectively.
The related compound 4-MeO-PV13 and the cyclohexanone derivative PV18 are known to have more potent psychoactive effects than alpha-PV9.
MeO-PV9 is a novel psychoactive substance derived from synthesizing the 4-methyl analog of the PV13 compound and 4-MeO pyrrolidinone.
4-meo-pv9 is a white, crystalline powder with a purity of 98% and an exact mass of 303.42. This product is a homolog of a similar compound with a lupus name of 1-(4-fluorophenyl)-2-(pyrrolidin-1-yl)octan-1-one and is related to similar compounds structurally. 4-meo-pv9 contains the exact mass and purity information on its label information sheet. It is intended for laboratory use only
4-meo-pv9 is a molecule that is assigned to the class of pyrrolidinones. It is an analog of 4-HO-PV8. This compound comes in powder form and is packaged in the standard 100mg format. Each order comes with written instructions and a certificate of analysis.
4-meo-pv9 is a stimulant of the cathinone class that produces powerful euphoria, focus and energy. Likewise, it increases sociability and libido. Users should expect significant stimulation, mood enhancement and alertness with 4-meo-pv9. Due to its powerful side effects, it is unsafe for first-time users.
4-meo-pv9 is a compound used to study serotonin receptor functioning and the effects of agents on it. The chemical belongs to a class of substances known as tryptamines. It has both hallucinogenic and stimulant properties, which makes it an interesting substance for researchers interested in developing more effective psychiatric medications that can be used to treat depression, anxiety and addictions.
4-MeO-PV9 is a powerful sedative that interacts with GABA receptors in the brain to produce a calming and relaxing effect. This compound is best used as part of a racemic mixture consisting of 50% 4-MeO-PV9 and 50% 5-MeO-MiPT (5-methyl methoxy indole).
To prepare the content, the following materials were used:
- FDA Substance Registration System
- Hazardous Substances Data Bank. National Library of Medicine. 28 August 2008. Retrieved 22 August 2014. 3,4-Methylenedioxymethamphetamine
- Liver transplant modulates gut microbial dysbiosis and cognitive function in cirrhosis. PDF . By HoChong Gilles, Scott C Matherly, Mohammed S Siddiqui, Puneet Puri...
- Differential impact of hyponatremia and hepatic encephalopathy on health-related quality of life and brain metabolite abnormalities in cirrhosis . By Jasmohan Bajaj
- An overview of alcohol and other drug issues
- Medicating the mind: a Kantian analysis of overprescribing psychoactive drugs B A Manninen
- The pharmacological basis of opioids Carla Ghelardini, Lorenzo Di Cesare Mannelli and Enrica Bianchi
- Ask Dr. Shulgin Online ARCHIVE: June 3, 2004
- Inhibition of plasma membrane monoamine transporters by β-ketoamphetamines. Nicholas V Cozzi, Michael KSievert, Alexander T Shulgin, Peyton JacobIII, Arnold Eruoho
- Schedules of Controlled Substances: Placement of Methylone Into Schedule I
- Bioanalysis of new designer drugs. Wohlfarth A, Weinmann W.
- New Psychoactive Substances (including synthetic cannabinoids, mephedrone, and more)
- Future Synthetic Drugs of Abuse. Donald A. Cooper. Drug Enforcement Administration McLean, Virginia
- Designer drugs: a medicinal chemistry perspective. F. Ivy Carroll Anita H. Lewin S. Wayne Mascarella Herbert H. Seltzman P. Anantha Reddy
- Synthetic cannabinoids in Europe
- Pharmacological Effects of MDMA in Man. By Enno Freye
- Drug Use in Relation to Outcome of Mammography Screening. von Euler-Chelpin M, Wu W, Vejborg and Lynge E
- DEA Drug Scheduling
- Electrophysiological Effects of Trace Amines on Mesencephalic Dopaminergic Neurons.Ada Ledonne, Nicola Berretta, Alessandro Davoli, Giada Ricciardo Rizzo, Giorgio Bernardi and Nicola Biagio Mercuri
- Electrophysiological evidence for a reciprocal interaction between amphetamine and cocaine-related drugs on rat midbrain dopaminergic neurons.Scarponi M, Bernardi G, Mercuri NB.
- Overdose of Drugs for Attention-Deficit Hyperactivity Disorder: Clinical Presentation, Mechanisms of Toxicity, and Management. Henry A. Spiller, author Hannah L. Hays Alfred Aleguas.
- Dose-dependent effectiveness of wheel running to attenuate cocaine-seeking: impact of sex and estrous cycle in rats. Peterson AB, Hivick DP, Lynch WJ.r.
- FDA Drug Safety Communication: Safety Review Update of Medications used to treat Attention-Deficit/Hyperactivity Disorder (ADHD) in children and young adults
- ADHD Medications and Risk of Serious Cardiovascular Events in Young and Middle-aged Adults
- Controlled Substances Act
- The Art of Drug Synthesis (Wiley Series on Drug Synthesis)
- Cannabis: domestic cultivation widespread
- A review of the influence of functional group modifications to the core scaffold of synthetic cathinones on drug pharmacokinetics
1kg $1690
300g $840
1kg $1690
1kg $1690
1kg $1690
out of stock
100g $580
1kg $1590
1kg $1590
500g $1080
200g $590